Updating results

38 results

Sort: Relevance | Date

Pyelonephritis (acute): antimicrobial prescribing (NG111)

This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Prostatitis (acute): antimicrobial prescribing (NG110)

This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published December 2018

Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Sore throat (acute): antimicrobial prescribing (NG84)

This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

Antimicrobial prescribing guideline Published January 2018

Otitis media (acute): antimicrobial prescribing (NG91)

This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

Antimicrobial prescribing guideline Published March 2018

Sinusitis (acute): antimicrobial prescribing (NG79)

This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

Antimicrobial prescribing guideline Published October 2017

Cough (acute): antimicrobial prescribing (NG120)

This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published February 2019

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published December 2018

Urinary tract infection (lower): antimicrobial prescribing (NG109)

This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)

This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published November 2018

Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279]

In development [GID-HST10014] Expected publication date: 14 August 2019

Highly specialised technologies guidance In development

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations ID1054

In development [GID-HST10025] Expected publication date: 08 January 2020

Highly specialised technologies guidance In development

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Highly specialised technologies guidance In development

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: 03 June 2020

Highly specialised technologies guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

In development [GID-HST10015] Expected publication date: TBC

Highly specialised technologies guidance In development

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-HST10021] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: TBC

Highly specialised technologies guidance In development

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 [ID943]

In development [GID-HST10008] Expected publication date: TBC

Highly specialised technologies guidance In development

Cellulitis and erysipelas: antimicrobial prescribing

In development [GID-NG10131] Expected publication date: 27 September 2019

Antimicrobial prescribing guideline In development

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Pneumonia (community-acquired): antimicrobial prescribing

In development [GID-NG10130] Expected publication date: 16 September 2019

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 13 December 2019

Antimicrobial prescribing guideline In development

Pneumonia (hospital-acquired): antimicrobial prescribing

In development [GID-NG10129] Expected publication date: 16 September 2019

Antimicrobial prescribing guideline In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 14 February 2020

Antimicrobial prescribing guideline In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 13 October 2020

Antimicrobial prescribing guideline In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development